Belgium· BE-AMP-SAM538915-00
Poteligeo 4 mg/ml
A mogamulizumab product containing mogamulizumab, registered in Belgium by Kyowa Kirin Holdings. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Mogamulizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX09 (mogamulizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Mogamulizumab · ATC L01FX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of mogamulizumab costs, country by country.
Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Mogamulizumab · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$432.02
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Mogamulizumab
- Manufacturer
- Kyowa Kirin Holdings
- Country
- Belgium (BE)
- ATC code
- L01FX09
- ATC class
- Mogamulizumab
- Defined daily dose
- 5 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7730047
- be_apb4183422
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
74 interactions on record for mogamulizumab.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mogamulizumab · interactions on record
74 records
- 29 severe
- 38 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Mogamulizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandPoteligeoOrifarm Oy
- IrelandPOTELIGEO 4 mg/mL concentrate for solution for infusionKyowa Kirin Holdings B.V.
- CzechiaPOTELIGEOKyowa Kirin Holdings B.V., Hoofddorp
- NorwayPoteligeoKyowa Kirin Holdings B.V.
- PolandPoteligeoKyowa Kirin Holdings B.V.
- SwedenPOTELIGEO 4 mg/ml Koncentrat till infusionsvätska, lösningKyowa Kirin Holdings B.V.
- IcelandPoteligeoKyowa Kirin Holdings B.V.
- SwitzerlandPoteligeo 4 mg/ml, Konzentrat zur Herstellung einer InfusionslösungKyowa Kirin Sàrl
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Poteligeo
- Liechtenstein · Poteligeo
- Norway · Poteligeo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a3e4f21b-ec0e-43e6-9079-0487f7b95bee GET /v1/drugs/a3e4f21b-ec0e-43e6-9079-0487f7b95bee?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Poteligeo 4 mg/ml",
"name_fr": "Poteligeo 4 mg/ml",
"name_nl": "Poteligeo 4 mg/ml",
"amp_code": "SAM538915-00",
"strengths": [
"4.0000"
],
"pack_count": 1,
"substances": [
"Mogamulizumab",
"Sodium Hydroxide",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Mogamulizumab",
"authorisation_numbers": [
"EU/1/18/1335/001"
]
}See everything about mogamulizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.